Scan other mental health players with potential catalysts on the horizon by shortlisting the curated 36 healthcare AI stocks that pair new treatment approaches with data and AI driven platforms.
To own COMPASS Pathways, you need to believe that COMP360 can move from an experimental therapy to a regulated treatment for difficult mental health conditions, starting with treatment resistant depression. The completed FDA New Drug Application is now the central short term catalyst, because it shifts the focus from finishing trials to regulatory review and launch execution.
The biggest near term risk still sits in regulatory timing and the cost of getting to launch. Management has guided to heavy cash use in 2025 and the business currently reports no revenue, so any delay, extra safety questions or slower than planned launch ramp could increase financing needs and pressure existing shareholders.
The analyst consensus Narrative on Simply Wall St pointed to the Phase 3 program and a rolling NDA as key triggers. That has now progressed into a full submission, supported by Phase 3 and Phase 2b data in more than 1,000 participants with treatment resistant depression, and framed by COMP360’s Breakthrough Therapy and UK ILAP designations.
For catalysts, your attention now sits on three linked execution questions: how the FDA review unfolds for treatment resistant depression; how prepared the commercial infrastructure really is for a potential launch; and how efficiently COMPASS Pathways can fund operations through to that point given its cash burn, shareholder dilution history and the absence of current product revenue.
COMPASS Pathways' narrative projects US$284.9 million in revenue and US$53.9 million in earnings by 2029. This implies yearly revenue growth from a zero base and an earnings increase of about US$246.3 million from a current loss of US$192.4 million.
Uncover why COMPASS Pathways' fair value indicates a 183% potential upside to its current price that could narrow quickly.
One alternate view on Compass Pathways focuses less on trial success and more on how quickly revenue might build after approval. The most optimistic analysts were modelling about US$743.4 million of revenue and US$32.5 million of earnings by 2029, compared with consensus at US$284.9 million and US$53.9 million. Those projections all pre date this FDA filing, so treat them as moving parts. It is important to explore several viewpoints before you decide how this catalyst fits your own expectations.
Explore 3 other COMPASS Pathways fair value estimates, including one that suggests as much as 1616% upside from the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis and judgment.
Once you have formed a view on COMPASS Pathways, it can help to compare it with other opportunities that suit different risk and income preferences. The Simply Wall St Screener offers several curated sets of stocks that you can scan quickly to see which ones match your own style.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com